FDA ERRATA (dated[removed]To FDA Advisory Committee Briefing Documents PULMONARY-ALLERGY DRUGS ADVISORY COMMITTEE MEETING April 7, 2010 NDA[removed]: Daxas (roflumilast 500 mcg tablets)

First Page		Document Content
Medicine Chemistry Benzamides Organofluorides Pyridines Roflumilast Chronic obstructive pulmonary disease Acute exacerbation of chronic obstructive pulmonary disease Chronic bronchitis Health Chronic lower respiratory diseases Smoking		FDA ERRATA (dated[removed]To FDA Advisory Committee Briefing Documents PULMONARY-ALLERGY DRUGS ADVISORY COMMITTEE MEETING April 7, 2010 NDA[removed]: Daxas (roflumilast 500 mcg tablets) Add to Reading List Source URL: www.fda.gov Download Document from Source Website File Size: 93,68 KB Share Document on Facebook

	Läkemedelsnytt Nr 3 – 18 mars 2011 Daxas (roflumilast): Nygammal farmakologisk princip för behandling av KOL En ny selektiv PDE-hämmare DocID: 1dajE - View Document
	Briefing Book - April 2010 DocID: Gi0Z - View Document
	FDA ERRATA (dated[removed]To FDA Advisory Committee Briefing Documents PULMONARY-ALLERGY DRUGS ADVISORY COMMITTEE MEETING April 7, 2010 NDA[removed]: Daxas (roflumilast 500 mcg tablets) DocID: G9xY - View Document
	Daxas® (roflumilast) Tablets NDA[removed]Pulmonary-Allergy Drugs Advisory Committee Meeting April 7, 2010 DocID: FTyj - View Document
	Q&A Slides Presented FDA PADAC Pulmonary-Allergy Drugs Advisory Committee Meeting April 7, 2010 DocID: FPD3 - View Document